INT98696

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 5.45
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (Dsg3) plasma membrane (Dsg3)
Dsg3 (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 4 49.16 Quite Low
Kinase C 13 5.00 Very Low Very Low Very Low
metalloproteinase 6 5.00 Very Low Very Low Very Low
agonist 5 5.00 Very Low Very Low Very Low
corticosteroid 2 5.00 Very Low Very Low Very Low
addiction 2 5.00 Very Low Very Low Very Low
Inflammatory mediators 1 5.00 Very Low Very Low Very Low
imagery 1 5.00 Very Low Very Low Very Low
antagonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Bullous Skin Disease 379 99.80 Very High Very High Very High
Disease 41 97.44 Very High Very High Very High
Blister 24 97.16 Very High Very High Very High
Adhesions 69 89.16 High High
Acantholysis 75 86.28 High High
Autoimmune Disease 11 75.00 Quite High
Skin Diseases 7 47.36 Quite Low
Targeted Disruption 3 43.52 Quite Low
Infection 2 40.88 Quite Low
Weight Loss 2 36.72 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In PV and PF, the AAb target the extracellular portions of desmoglein 3 (Dsg3) and Dsg1, respectively.
Regulation (target) of Dsg3 associated with bullous skin disease
1) Confidence 0.45 Published 2001 Journal Skin Pharmacol. Appl. Skin Physiol. Section Abstract Doc Link 11598441 Disease Relevance 2.09 Pain Relevance 0
In PV and PF, the AAb target the extracellular portions of desmoglein 3 (Dsg3) and Dsg1, respectively.
Regulation (target) of desmoglein 3 associated with bullous skin disease
2) Confidence 0.45 Published 2001 Journal Skin Pharmacol. Appl. Skin Physiol. Section Abstract Doc Link 11598441 Disease Relevance 2.09 Pain Relevance 0
Pemphigus vulgaris (PV) patients develop autoantibodies that target desmoglein (DSG) 3 and under certain conditions desmoglein (DSG) 1 [1].
Regulation (target) of desmoglein associated with bullous skin disease
3) Confidence 0.39 Published 2010 Journal Dermatology Research and Practice Section Body Doc Link PMC2879910 Disease Relevance 0.85 Pain Relevance 0
Finally, it has to be noted that, if direct inhibition occurs, it is not possible to discriminate at present whether interference with Dsg 3 binding in PV was mediated by steric hindrance, i.e. by blocking trans-interaction of desmoglein molecules by the bound autoantibody, or rather by allosteric effects, i.e. autoantibody-induced conformational changes of the Dsg 3 ectodomain, which in turn interfere with Dsg 3 transinteraction.
Regulation (changes) of Dsg 3 associated with bullous skin disease
4) Confidence 0.14 Published 2008 Journal Histochem Cell Biol Section Body Doc Link PMC2413110 Disease Relevance 0.42 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox